Millennium Capital Advisors LLC Takes $1.09 Million Position in Pfizer Inc. $PFE

Key Points

• Millennium Capital Advisors disclosed a new fourth-quarter stake in Pfizer, buying 43,687 shares valued at about $1.09 million.
• Pfizer reported better-than-expected Q1 results, with EPS of $0.75 versus $0.72 expected and revenue of $14.45 billion versus $13.84 billion anticipated.
• The company declared a quarterly dividend of $0.43 per share, implying a high annualized yield of about 6.8%, while analysts currently rate the stock a consensus Hold.

Millennium Capital Advisors LLC acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 43,687 shares of the biopharmaceutical company's stock, valued at approximately $1,088,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Franklin Resources Inc. lifted its stake in Pfizer by 47.8% in the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company's stock worth $638,787,000 after acquiring an additional 8,108,887 shares during the last quarter. Vanguard Group Inc. lifted its stake in Pfizer by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company's stock worth $13,479,520,000 after acquiring an additional 7,031,162 shares during the last quarter. Neuberger Berman Group LLC lifted its stake in Pfizer by 203.8% in the third quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company's stock worth $229,346,000 after acquiring an additional 6,045,763 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in Pfizer by 48.2% in the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company's stock worth $468,174,000 after acquiring an additional 5,978,927 shares during the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of Pfizer by 120.9% during the 3rd quarter. AQR Capital Management LLC now owns 9,505,615 shares of the biopharmaceutical company's stock worth $230,986,000 after buying an additional 5,202,884 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of Pfizer stock opened at $25.31 on Friday. The firm's fifty day simple moving average is $26.98 and its 200-day simple moving average is $26.19. The stock has a market capitalization of $144.25 billion, a price-to-earnings ratio of 19.32 and a beta of 0.35. Pfizer Inc. has a 12 month low of $22.45 and a 12 month high of $28.75. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to analysts' expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer's revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer's payout ratio is currently 131.30%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on PFE shares. Citigroup boosted their price objective on shares of Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 29th. BMO Capital Markets restated an "outperform" rating and set a $30.00 price objective on shares of Pfizer in a research report on Monday, March 9th. Cantor Fitzgerald restated a "neutral" rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday, February 4th. Weiss Ratings upgraded shares of Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a research report on Wednesday, May 6th. Finally, Barclays started coverage on shares of Pfizer in a research report on Thursday, February 19th. They set an "underweight" rating and a $25.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Pfizer has an average rating of "Hold" and a consensus price target of $28.84.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced a Europe label expansion for its hemophilia therapy Hympavzi, which could broaden the drug’s commercial opportunity and support long-term revenue growth.
• Positive Sentiment: Multiple updates highlighted ongoing clinical and development activity, including a new Korea migraine study for Nurtec ODT, a Phase 1 food-effect study for PF-07799933, a prazosin site-transfer trial, and a planned Japan RSV vaccine trial. These reinforce Pfizer’s pipeline and global expansion efforts.
• Positive Sentiment: Recent commentary around Pfizer’s Q1 earnings pointed to improving momentum in new and acquired products, especially oncology and migraine treatments, as well as progress from the Seagen integration and legal settlements that may improve clarity around future cash flow.
• Neutral Sentiment: Media coverage also noted that investor sentiment remains mixed, with some analysts and commentators arguing Pfizer still lacks strong earnings momentum and is being supported more by its dividend and defensive valuation than by a clear near-term growth catalyst.
• Negative Sentiment: Pfizer continues to face concerns about declining COVID-related sales and looming patent expirations, which have weighed on the stock even after earnings beat expectations.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.